29 -2 (40) 2022 — Akhmedova M.D., Imamova I.A. — THE STATE OF HEMOSTASIS IN COVID-19 ON THE BACKGROUND OF VIRAL CHRONIC HEPATITIS

THE STATE OF HEMOSTASIS IN COVID-19 ON THE BACKGROUND OF VIRAL CHRONIC HEPATITIS

Akhmedova M.D., Tashkent Medical Academy, Tashkent, Uzbekistan

Imamova I.A., Tashkent Medical Academy, Tashkent, Uzbekistan

Ruzhentsova T.A., Moscow Research Institute of Epidemiology and Microbiology named after G. N. Gabrichevsky Rospotrebnadzor, Moscow, RF

Mirzazhonova D.B., Republican Specialized Scientific and Practical Medical Center for Epidemiology, Microbiology, Infectious and Parasitic Diseases, Tashkent, Uzbekistan

Nazirov Sh.A. Tashkent Medical Academy, Tashkent, Uzbekistan

Resume

Objective: A detailed study of the pathogenetic foundations of disorders in the blood coagulation system in patients with COVID-19 against the background of chronic viral hepatitis will improve the medical care provided to this category of patients. For, it is hemodynamic disorders that are the main reason for the development of complications, both with COVID-19 and with liver diseases.

Based on the literature review, the article presents the relationship between changes in hemostasis and infections, as well as the role of severe endotoxemia in triggering the release of pro-inflammatory cytokines and oxidative stress, which not only activate intravascular coagulation, negatively affect vascular-platelet hemostasis, but also can progress liver fibrosis . The possible causes of the formation of a stable thrombus and laboratory parameters used to determine the specific cause of coagulopathy are listed.

Key words: COVID-19, chronic viral hepatitis, hemostasis, blood clotting factors.

First page

151

Last page

159

For citation: Akhmedova M.D., Imamova I.A., Ruzhentsova T.A., Mirzazhonova D.B., Nazirov Sh.A. THE STATE OF HEMOSTASIS IN COVID-19 ON THE BACKGROUND OF VIRAL CHRONIC HEPATITIS //New Day in Medicine 2(40)2022 151-159 https://cutt.ly/GActaKh

LIST OF REFERENCES:

1. Никифоров В.В., Суранова Т.Г., Чернобровкина Т.Я., Янковская Я.Д., Бурова С.В. Новая коронавирусная инфекция (COVID-19): клинико-эпидемиологические аспекты. Архивъ внутренней медицины. 2020;10(2):87-93. https://doi.org/10.20514/2226-6704-2020-10-2-87-93
2. WHO: Weekly epidemiological update – 5 January 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update—5-january-2021. Accessed on 09.01.2021
3. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) (версия 6 от 24.04.2020)». – М., 2020. -142 с.
4. Wang D., Yin Y., Hu C., Liu X.., Zhang X., Zhou S., Jian, M., Xu H., Prowle J., Hu B. et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit. Care 2020, 24, 188 [PubMed]
5. Tan W., Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease // Int J Cardiol. 2020. doi: 10.1016/j.ijcard.2020.03.063.
6. Wang X., Zheng J., Guo L., Yao H., Wang L., Xia X. et al. Fecal viral shedding in COVID-19 patients: Clinical significance, viral load dynamics and survival analysis // Virus Res. 2020 Nov;289:198147. DOI: 10.1016/j.virusres.2020.198147
7. Муркамилов И.Т., Айтбаев К.А. Фомин В.В., Юсупов Ф.А., Муркамилова Ж.А. Новая коронавирусная инфекция (covid-19) и нефро-цереброваскулярная система //The scientific heritage. 2020. №46. С.42-49
8. Li Y.C., Bai W.Z., Hashikawa T. The neuroinvasive poten-tial of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;10.1002/jmv.25728. doi:10.1002/jmv.25728
9. Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in pa-tients with COVID-19?. Eur Heart J. 2020; ehaa235. doi:10.1093/ eurheartj/ehaa235
10. Романов Б.К. Коронавирусная инфекция COVID-2019.- Безопасность и риск фармакотерапии 2020. Т. 8, № 1. – С. 3-8 
11. Самородов А.В., Золотухин К.Н. Профилактика COVID-19-ассоциированного нарушения гемостаза у пациента со стентированными коронарными артериями. Клинический случай. Креативная хирургия и онкология. 2020;10(2):137-142. https://doi.org/10.24060/2076-3093-2020-10-2-137-142
12. Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // Lancet Respir Med. – 2020. – No.8. – Р.  475–481. – doi: 10.1016
13. Wool G.D., Miller J.L. The Impact of COVID-19 Disease on Platelets and Coagulation // Pathobiology. 2021. Т88, №1. Р.15-27. doi: 10.1159/000512007.
14. Ciceri F., Beretta L., Scandroglio A.M., Colombo S., Landoni G., Ruggeri A., et al. Microvascular COVID-19 lung vessels obstructive thromboinl ammatory syndrome (Microclots): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020 Apr 15. Online ahead of print. PMID: 32294809
15. Баранич А.И. Коагулопатии в остром периоде тяжелой черепно-мозговой травмы Дисс.к.м.н.С.117 Москва 2020
16. Минов А.Ф., Дзядзько А.М., Руммо О.О. Нарушения гемостаза при заболеваниях печени. – Вестник трансплантологии и искусственных органов Том XII № 2-2010. С.82-91.
17. Windyga J.: COVID-19 a zaburzenia hemostazy. Med. Prakt., 2020; 7-8: 59–68
18. Галеева Н.В., Кравченко И.Э. Показатели гемостаза у больных хроническим гепатитом с // Эпидемиология и инфекционные болезни. 2018. №6. URL: https://cyberleninka.ru/article/n/pokazateli-gemostaza-u-bolnyh-hronicheskim-gepatitom-s (дата обращения: 07.01.2021).
19. Морозов Ю.А., Медников Р.В., Чарная М.А. Нарушения системы гемостаза при патологии печени и их диагностика // Геморрагические диатезы, тромбозы, тромбофилии. 2014. №1. URL: https://cyberleninka.ru/article/n/narusheniya-sistemy-gemostaza-pri-patologii-pecheni-i-ih-diagnostika (дата обращения: 07.01.2021).
20. Глобальная стратегия сектора здравоохранения по вирусному гепатиту 2016–2021 гг.: на пути к ликвидации вирусного гепатита. ВОЗ, 2016. 52 с.